Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.33.05 CHF
Change Today +0.90 / 2.80%
Volume 2.8K
PFE On Other Exchanges
Symbol
Exchange
Xetra
Stockholm
London
Sao Paulo
Bogota
As of 12:43 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE) Snapshot

Open
SFr.32.85
Previous Close
SFr.32.15
Day High
SFr.33.05
Day Low
SFr.32.85
52 Week High
03/16/15 - SFr.34.72
52 Week Low
08/8/14 - SFr.25.40
Market Cap
202.9B
Average Volume 10 Days
2.0K
EPS TTM
--
Shares Outstanding
6.1B
EX-Date
02/4/15
P/E TM
--
Dividend
SFr.1.07
Dividend Yield
2.94%
Current Stock Chart for PFIZER INC (PFE)

pfizer inc (PFE) Details

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

78,300 Employees
Last Reported Date: 02/27/15
Founded in 1849

pfizer inc (PFE) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.3M
President of Worldwide Research and Developme...
Total Annual Compensation: $1.2M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $1.2M
Group President of Global Established Pharma ...
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2014.

pfizer inc (PFE) Key Developments

Pfizer Inc. Announces Oral Tofacitinib Meets Primary Endpoints in Pivotal Phase 3 Psoriasis Trials

Pfizer Inc. announced the presentation of detailed pooled results from two pivotal Phase 3 studies from the Oral treatment P soriasis Trials (OPT) program at the 73rd American Academy of Dermatology (AAD) Annual Meeting. These results, evaluating the efficacy and safety of tofacitinib citrate for the treatment of adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, have been selected for oral presentation during the Pearls from the Posters New and Noteworthy Research Finds. Additionally, an integrated analysis of safety data from the OPT global clinical development program for tofacitinib was presented during the Late-Breaking Research in Dermatology Forums. The detailed, pooled analysis of 16 week data from the OPT Pivotal #1 and OPT Pivotal #2 studies showed that tofacitinib 10 mg and 5 mg tablets twice daily met the co-primary efficacy endpoints of superiority over placebo at 16 weeks in the proportion of patients achieving a Physicians Global Assessment (PGA) response of clear or almost clear, and the proportion of patients achieving at least a 75% reduction in Psoriasis Area and Severity Index (PASI75), two commonly used measures of efficacy in psoriasis. Both the tofacitinib 10 mg and 5 mg twice-daily doses showed statistically significant superiority over placebo for key secondary efficacy endpoints presented at AAD, including proportion of patients achieving ?90% reduction in PASI (PASI90) relative to baseline at Week 16% change from baseline in Body Surface Area (BSA) at Week 16, change from baseline in Dermatology Life Quality Index (DLQI) at Week 16, and percentage change from baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16 in patients with nail psoriasis.

Pfizer Inc. Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015

Pfizer Inc. Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015 . Venue: JW Marriott Denver at Cherry Creek, 150 Clayton Lane, Denver, CO 80206, United States.

Pfizer & Eli Lilly to Resume Tanezumab Phase 3 Program

Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with the collaboration agreement. A partial clinical hold has been in place for tanezumab and all other anti-nerve growth factor antibodies since December 2012 due to adverse changes in the sympathetic nervous system of mature animals. U.S. FDA decided to lift the partial clinical hold after a review of a robust body of nonclinical data characterizing the sympathetic nervous system response to tanezumab. The data were submitted to the FDA in February 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:SW SFr.33.05 CHF +0.90

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merck & Co Inc $57.75 USD +0.15
Nestle SA SFr.73.10 CHF -0.10
Novartis AG SFr.96.20 CHF +0.40
Roche Holding AG SFr.263.20 CHF -0.70
Procter & Gamble Co/The $82.31 USD +0.16
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 24.4x
Price/Sales 4.4x
Price/Book 3.0x
Price/Cash Flow 16.1x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.